Aktienanalyse zu Neurocrine Biosciences, Inc (NBIX)NBIXNeurocrine Biosciences, Inc

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. It is engaged in discovering, developing, and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine, and immunological disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its first-in-class commercial portfolio includes INGREZZA (valbenazine) and CRENESSITY (crinecerfont). It also offers VYKAT XR (diazoxide choline) extended-release tablets, for the treatment of hyperphagia in adults and pediatric patients four years of age and older with Prader-Willi syndrome (PWS). Its pipeline includes direclidine / (M4 Agonist), osavampator॥ / (AMPA PAM) and others. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Neurocrine Biosciences Inc is currently a hold. The stock is priced at $135.71, which is significantly below the average analyst price target of $214, indicating potential upside. However, the RSI is at 30.999, suggesting the stock is oversold, and there are concerns regarding the safety of its product VYKAT XR, which could impact future revenues. The forward P/E ratio of 14.1243 indicates a reasonable valuation, but the recent 5-day change of -4.72% raises caution about short-term performance.

13 analysts cover NBIX: 13 rate it Buy, 0 Hold and 0 Sell. The average price target is 179.68.